Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 Clinical Trial

Official title:

Phase II Pilot Study of Subsequent Line Gemcitabine and Nivolumab for Advanced SCLC

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03662074
• Other study ID #: IRB00051024
• Secondary ID: NCI-2018-01803CC
• Status: Terminated
• Phase: Phase 2
• Start date: November 7, 2018
• Est. completion date: February 3, 2022

Study information

• Verified date: July 2023
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II pilot trial studies how well gemcitabine and nivolumab work in treating participants with small cell lung cancer that has spread to other parts of the body after other treatments have failed. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving second-line gemcitabine and nivolumab may work better in treating participants with small cell lung cancer.

Description:

PRIMARY OBJECTIVES: I. To compare response rate (RR) of gemcitabine and nivolumab (G+N) after 4 cycles (8 weeks) to historical controls treated with nivolumab alone. SECONDARY OBJECTIVES: I. To compare median overall survival (OS) of G+N to historical controls treated with nivolumab alone. II. To compare median progression-free survival (PFS) of G+N to historical controls treated with nivolumab alone. III. To evaluate for tolerability of G+N at each treatment cycle and then every 8 weeks after treatment is completed. EXPLORATORY OBJECTIVES: I. To correlate immunophenotypic changes among lymphocytes (quantitative measurements of CD4 and CD8 T-cells) with radiographic response and overall survival before treatment, after treatment and between 8-12 weeks after treatment. II. Among those patients with tumor mutation burden (TMB) status available, to describe the association between TMB (low, medium, or high) and RR, OS, and PFS. III. Assess the patient perspective of symptomatic adverse events using self-reported items from the National Cancer Institute (NCI) Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE). OUTLINE: Participants receive gemcitabine intravenously (IV) over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants are followed up at 30 days, 6-10 weeks, and every 8 weeks thereafter.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: February 3, 2022
• Est. primary completion date: October 7, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed incurable SCLC and have had prior treatment with platinum-based chemotherapy. High-grade neuroendocrine tumors that are suspected to be of bronchopulmonary origin can be enrolled if they have had prior treatment with a SCLC chemotherapy regimen (e.g. platinum plus etoposide).
• Patients should not be demonstrating end-organ damage due to rapid progression of disease based on the most recent assessment of the treating physician.
• Patients must have radiographically measurable metastatic disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Absolute neutrophil count >= 1,500/mcL.
• Platelets >= 100,000/mcL.
• Chemotherapy agents are known to be teratogenic, therefore women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document.

Exclusion Criteria:

• Patients who have previously received either gemcitabine or an immune checkpoint inhibitor can be enrolled.
• Emergent need for palliative radiation.
• Patients may not be receiving any other investigational agents for the treatment of nonsmall cell lung cancer.
• History of allergic reaction to gemcitabine.
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects with chemotherapy. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy, breastfeeding should be discontinued.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Carcinoma
• Stage IV Lung Cancer AJCC v8
• Stage IVA Lung Cancer AJCC v8
• Stage IVB Lung Cancer AJCC v8

Intervention

Drug:
• Gemcitabine
Given IV

Biological:
• Nivolumab
Given IV

Locations

Country	Name	City	State
United States	Wake Forest University Health Sciences	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Positive Responses to Therapy Per Response Evaluation Criteria in Solid Tumors (RECIST)	Objective RR (complete response [CR] + partial response [PR]) will be compared between this study sample and a historical benchmark value of 10%. For this comparison we will use a one-sample test of proportion.; Complete Response (CR): Disappearance of all target lesions.; Partial Response (PR): Decrease by = 30% in sum of longest diameter of target lesions.; Stable Disease (SD): Not meeting criteria for CR, PR, or PD.; Progressive Disease (PD): Increase by = 20% in sum of longest diameter of target lesions or the appearance of one or more new lesions.; The response in non-target lesions is defined as follows: Complete Response (CR): Complete disappearance of all non-target lesions.; Stable Disease (SD): Persistence of one or more non-target lesion(s).; Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.	Up to 8 weeks
Secondary	Overall Survival (OS) - Number of Participants	OS will be estimated using standard Kaplan Meier survival analysis methods.	Duration of time from the start of treatment to date of death, assessed up to 2 years
Secondary	Overall Survival (OS) - Months	A median value (months) of overall survival will be estimated using standard Kaplan Meier survival analysis methods.	Duration of time from the start of treatment to date of death, assessed up to 2 years
Secondary	Progression-free Survival (PFS) - Number of Participants	Progression-free survival will be estimated using standard Kaplan Meier survival analysis methods. Progression-Free Survival (PFS) is defined as the duration of time from the start of treatment to the time of investigator assessed progression or death. Progressive Disease (PD): Increase by = 20% in sum of longest diameter of target lesions or the appearance of one or more new lesions	Duration of time from the start of treatment to the time of investigator assessed progression or death, assessed up to 2 years
Secondary	Progression-free Survival (PFS) - Months	A median value (months) of progressive-free survival will be estimated using standard Kaplan Meier survival analysis methods. Progressive Disease (PD): Increase by = 20% in sum of longest diameter of target lesions or the appearance of one or more new lesions	Duration of time from the start of treatment to the time of investigator assessed progression or death, assessed up to 2 years
Secondary	Number of Adverse Events	Toxicity rates will be estimated by responder status and presented overall and by body site per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Up to 2 years